Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor

References

• Bi TQ, Che XM. (2010). Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 10:119–25.
   PubMed Web of Science ®Google Scholar
• Bi TQ, Che XM, Liao XH, et al. (2011). Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep 26:1251–7.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–27.
   PubMedGoogle Scholar
• Burgos ES. (2011). NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr Med Chem 18:1947–61.
   PubMed Web of Science ®Google Scholar
• Check JH, Sansoucie L, Chern J, Dix E. (2010). Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res 30:119–22.
   PubMed Web of Science ®Google Scholar
• Chiarugi A, Dolle C, Felici R, Ziegler M. (2012). The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 12:741–52.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
   PubMed Web of Science ®Google Scholar
• Garcea G, Chee W, Ong SL, Maddern GJ. (2010). Preoperative biliary drainage for distal obstruction: the case against revisited. Pancreas 39:119–26.
   PubMed Web of Science ®Google Scholar
• Garten A, Petzold S, Korner A, et al. (2009). Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 20:130–8.
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70.
   PubMed Web of Science ®Google Scholar
• Halladay JS, Delarosa EM, Tran D, et al. (2011). High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis. Drug Metab Lett 5:220–30.
   PubMedGoogle Scholar
• Halladay JS, Wong S, Khojasteh SC, Grepper S. (2012). An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes. J Pharmacol Toxicol Methods 66:270–5.
   PubMed Web of Science ®Google Scholar
• Holen K, Saltz LB, Hollywood E, et al. (2008). The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26:45–51.
   PubMed Web of Science ®Google Scholar
• Hovstadius P, Larsson R, Jonsson E, et al. (2002). A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 8:2843–50.
   PubMed Web of Science ®Google Scholar
• Khan JA, Forouhar F, Tao X, Tong L. (2007). Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 11:695–705.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013a). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53:167–77.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013b). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 53:178–91.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–95.
   PubMed Web of Science ®Google Scholar
• Mukadam S, Tay S, Tran D, et al. (2012). Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug Metab Lett 6:43–53.
   PubMedGoogle Scholar
• O'Brien T, Oeh J, Xiao Y, et al. (2013). Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Neoplasia 15:1314–29.
   PubMed Web of Science ®Google Scholar
• Olesen UH, Thougaard AV, Jensen PB, Sehested M. (2010). A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 9:1609–17.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Cerny T, Terret C, et al. (2005). Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41:702–7.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci 100:4090–110.
   PubMed Web of Science ®Google Scholar
• Sampath D, Zabka TS, Misner DL, et al. (2015). Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol Ther 151:16–31.
   PubMed Web of Science ®Google Scholar
• Shackelford RE, Bui MM, Coppola D, Hakam A. (2010). Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol 3:522–7.
   PubMed Web of Science ®Google Scholar
• Tan B, Young DA, Lu ZH, et al. (2013). Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD + biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem 288:3500–11.
   PubMed Web of Science ®Google Scholar
• Tarrant JM, Dhawan P, Singh J, et al. (2015). Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid. Toxicol Mech Methods 25:201–11.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG. (2011). Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10:671–84.
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Marathe P, He H, Jones RD, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 100:4111–26.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60.
   PubMed Web of Science ®Google Scholar
• Wang B, Hasan MK, Alvarado E, et al. (2011). NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30:907–21.
   PubMed Web of Science ®Google Scholar
• Wong H, Choo EF, Alicke B, et al. (2012). Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18:3846–55.
   PubMed Web of Science ®Google Scholar
• Yu S, Li S, Yang H, et al. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250–4.
   PubMed Web of Science ®Google Scholar
• Zabka TS, Singh J, Dhawan P, et al. (2015). Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol Sci 144:163–72.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li L, Chen L, et al. (2011a). Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode. J Mol Biol 407:13–20.
   PubMed Web of Science ®Google Scholar
• Zhang HX, Yang CB, Guo L, Deng ZH. (2011b). Forensic identification by coding of frontal sinus characteristics of CT. Fa Yi Xue Za Zhi 27:13–16.
   PubMedGoogle Scholar
• Zhang LQ, Heruth DP, Ye SQ. (2011c). Nicotinamide phosphoribosyltransferase in human diseases. J Bioanal Biomed 3:13–25.
   PubMedGoogle Scholar
• Zhang Y, Yao L, Lin J, et al. (2010). Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci 99:3620–7.
   PubMed Web of Science ®Google Scholar
• Zheng X, Bauer P, Baumeister T, et al. (2013). Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. J Med Chem 56:6413–33.
   PubMed Web of Science ®Google Scholar